NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









EraCal Therapeutics

EraCal Therapeutics

Private
SchlierenHealthcare & Life Scienceshttps://www.eracal.ch/

Last Round

Seed

Oct 16, 2019

Total Funding Raised

$1.14M

Company Overview

EraCal Therapeutics is a biotechnology company that develops drugs to treat metabolic syndrome and obesity using its in-vivo screening platform.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

drug discoveryzebrafish screeningobesity treatmentappetite suppressorphenotypic screeningweight loss drugssmall molecule drugsbiopharma licensingmetabolic diseasepreclinical drug developmentnovel drug targetszebrafish modelin-vivo screening

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

EraCal Therapeutics Comparables

Compare EraCal Therapeutics with similar companies based on industry and business-model similarity.

EraCal Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

EraCal Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedOct 16, 2019
GrantFeb 1, 2019

EraCal Therapeutics Investors

Notable investors and investment history

EraCal Therapeutics investors
InvestorRounds
University of ZurichSeed
RedalpineSeed
Venture KickGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 3, 2025

    Monthly visitors increased 151% MoM, reaching 1.1K.

  • Jun 1, 2025

    Monthly visitors grew 91% MoM.

EraCal Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

EraCal Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about EraCal Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSchlieren
Employee Range4
Year Founded2018
Last FundingOct 16, 2019

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.